Accountability for the Diversity Plan to Improve Enrollment of Underrepresented Populations in Clinical Trials
November 30, 2022
Co-founder and CEO, Acclinate
SVP of Research and Strategy, Medable
CEO, Touch, The Black Breast Cancer Alliance
Director, Global Representation in Clinical Research, Amgen
Director, Digital Clinical Trials at Scripps Research and Principal Science Officer at CareEvolution, Inc
Sr. Director and Head, Global Demographics & Diversity, GSK
Co-Founder at Lightship
Everyone’s talking about the lack of diversity, equity, and inclusion in clinical trials. The FDA issued draft guidance to provide recommendations to help clinical trial sponsors develop a Race and Ethnicity Diversity Plan. Some House Democrats are also pushing for Congressional legislation to secure more representation in clinical trials. We all recognize the need to do something about it, but who’s going to lead the efforts? Who’s going to be accountable for increasing diversity in clinical trials?
Leaders from across the clinical trials ecosystem give an update on the Diversity, Equity, and Inclusion in Digitized Clinical Trials project, and an in-depth discussion on what different stakeholders can do to ensure digital technologies are used to increase diversity, equity, and inclusion in clinical trials.